Giving Grants
Private foundations generally make use of grants to individuals or other charities, as opposed to direct funding of their own programs. A public charity, in contrast, tends to carry out some kind of direct activity, such as operating a homeless shelter. The only substantive change between the two is the manner in which funds are acquired. The "public" in "public charity" refers to the solicitation of periodic donations from the community. The amount of these donations is used to determine a quantifiable intensity of public support, which is necessary in order to achieve status as a "public charity."
Best Bank Companies To Watch In Right Now: NuVasive Inc.(NUVA)
NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedures for the spine. The company?s products focus on applications for spine fusion surgery. It offers products primarily for the thoracolumbar spine and cervical spine. The company?s principal products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines four categories of product offerings, including NVM5 and NVJJB, its proprietary software-driven nerve monitoring systems; MaXcess system that provides access to the spine with minimal soft tissue disruption; specialized implants that are used for interbody disc height restoration for fusion and stabilization of the spine, as well as biologic products comprising FormaGraft, a collagen-based synthetic bone substitute and Osteocel Plus, an allograft cellular ma trix. Its biologic products also comprise AttraX, a synthetic bone graft material; and Triad, an allograft cellular matrix containing viable mesenchymal stem cells. In addition, the company offers a range of bone allograft in patented saline packaging; disposables and spine implants under the CoRoent brand name; and fixation devices, such as rods, plates, and screws. Further, it provides intra-operative monitoring services for insight into the nervous system during spine and other surgeries. Additionally, the company is developing total disc replacement devices for lateral lumbar spine and cervical spine applications. NuVasive, Inc. sells its products through directly-employed sales shareowners, independent sales agents, and distributors to surgeons and hospitals in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Wednesday’s session are Bank of America Corp.(BAC), Chelsea Therapeutics International Ltd.(CHTP) and NuVasive Inc.(NUVA)
5 Best Income Stocks To Buy For 2015: Flushing Financial Corporation (FFIC)
Flushing Financial Corporation operates as the holding company of Flushing Savings Bank, FSB that provides banking products and services primarily to consumers and businesses. The company?s deposit products include savings accounts, money market accounts, demand accounts, negotiable order of withdrawal accounts, and certificates of deposit. Its loan products portfolio comprises one-to-four family, multi-family residential, and commercial real estate mortgage loans; construction loans, primarily for residential properties; small business administration loans and other small business loans; mortgage loan surrogates, such as mortgage-backed securities; U.S. government securities, corporate fixed-income securities, and other marketable securities; and consumer loans, including overdraft lines of credit. The company also offers Internet banking services through iGObanking.com. As of December 31, 2010, it conducted its business through 16 full-service offices located in the New York City Boroughs of Queens, Brooklyn, and Manhattan, as well as in Nassau County, New York. The company was founded in 1929 and is based in Lake Success, New York.
Advisors' Opinion:- [By Tim Melvin]
I always find it very interesting to see what long-term investors are selling in a given quarter. Kahn Brothers lightened up on many financials that have shot up and now trade above book value. The firm sold out of Flushing Financial (FFIC), TCF Financial (TCB) and Dime Community Bank (DCOM). Khan apparently shares my views on the large-cap drug stocks, easing up on both Pfizer (PFE) and Bristol Meyers (BMY) over the summer. Khan Brothers also sold the last of the Travelers shares (TRV) it has owned since 2008 at more than twice the purchase price.
- [By Marc Bastow]
Savings and loan holding company Flushing Financial (FFIC) raised its quarterly dividend 15% to 15 cents per share, payable March 28 to shareholders of record as of March 7.
FFIC Dividend Yield: 2.86%
5 Best Income Stocks To Buy For 2015: J.C. Penney Company Inc. Holding Company(JCP)
J. C. Penney Company, Inc., through its subsidiary, J. C. Penney Corporation, Inc., operates department stores in the United States and Puerto Rico. The company sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products, and home furnishings. It also provides various services, such as styling salon, optical, portrait photography, and custom decorating. The company also sells its products through its Internet Web site, jcp.com. J. C. Penney Company, Inc. has strategic alliance with Martha Stewart Living Omnimedia, Inc. As of December 7, 2011, it operated approximately 1,100 department stores. The company was founded in 1902 and is based in Plano, Texas.
Advisors' Opinion:- [By Ben Eisen]
Perpetually struggling department store J.C. Penney Co. (JCP) �said it expects a sales boost this holiday season as it returns to a promotional strategy. But for the most part, retailers including Dollar Tree Inc. (DLTR) �, GameStop Corp. (GME) � and Abercrombie & Fitch Co. (ANF) � gave dour outlooks in their earnings reports.
- [By Rick Aristotle Munarriz]
Alamy Sometime, companies can make brilliant moves; other times, things don't work out quite as planned. From an airline overpaying its departing CEO to a new way to eat a waffle in the morning, here's a rundown of this week's best and worst results from the business world. Cedar Fair (FUN) -- Winner There were plenty of reasons to expect amusement park operator Cedar Fair to post lower revenue than it did a year earlier. The crowd-drawing Easter holiday slipped into the first quarter this year. Cedar Fair sold ones of its parks. There was one week less in the second quarter than during last year's period. More importantly, rival Six Flags (SIX) posted a 3 percent decline in revenue during the same period a few days ago. However, the parent company of Cedar Point and Knott's Berry Farm came through with a 1 percent uptick in revenue as guest spending was more than enough to offset the slowing turnstile clicks. This may be a small step, but it's welcome at a time when it faced the same fierce headwinds that many of its coaster rides do. J.C. Penney (JCP) -- Loser Activist investor Bill Ackman is raising a stink at J.C. Penney. Has he forgotten what happened the last time? Ackman is frustrated that the chain has stuck to former CEO Mike Ullman as its interim helmsman for too long. He wants the stumbling retailer to rush the process and bring another former J.C. Penney CEO to step in as chairman of the board. The problem here is that it was Ackman that pushed for J.C. Penney to bring on Apple Store mastermind Ron Johnson to rescue the chain two years ago. The makeover went terribly, and sales fell sharply as Johnson's moves alienated loyal shoppers without wooing new customers. Ackman is an accomplished investor, but it's hard to take him seriously here. Yum! Brands (YUM) -- Winner The parent company behind Taco Bell, KFC, and Pizza Hut made the cut in this weekly column last week after introducing a fast casual concept called KFC eleven that upgrades the me
- [By Ben Levisohn]
Just like its stores, JC Penney’s (JCP) financial results had something for everyone–and shares of the beaten-down retailer have jumped as a result.
JC Penney report a loss of $1.15 a share, beating the Street consensus for a loss of $1.25, on sales of $2.8 billion, beating forecasts for $2.71 billion. Same-store sales rose 6.2%, above forecasts for 4%. JC Penney also said that its gross margin rose to 33.1% of sales, up from 30.8% from the same quarter a year ago. For those worried about JC Penney’s cash, the company said that it had received a $2.35 billion credit line to replace a $1.85 billion one.
Of course, JC Penney’s financial results would be incomplete without its guidance. For the full year, JC Penney said it expects same-store sales to “increase mid-single digits,” while gross margin should “improve significantly versus 2013.” Free cash flow should be breakeven, JC Penney said.
Color Belus Capital’s Brian Sozzi impressed:
JC Penney�� 1Q14 report basically says this in a nutshell: the return to old school department store retailing principles (promotions), with an infusion of flare in key departments (teens, athletic wear), is a recipe that could bring the company to the land of profits for the upcoming holiday season.� Believe me, it�� almost unimaginable to utter such words after having a sell rating on the stock for two years, and only issuing an upgrade on April 10.
But, push comes to shove, when the weather was conducive to spending the better merchandized JC Penney reconnected with its lapsed customers, disenchanted Target (TGT) customers (Target�� apparel section in men and women has gotten very, very poor), and Kohl�� (KSS) customers to deliver a quarter that removes the company further away from the bankruptcy equation.
Shares of JC Penney have gained 18% to $9.84 at 4:12 p.m. in after-hours trading, after dropping 2.8% today. Target h
5 Best Income Stocks To Buy For 2015: CEL-SCI Corp (CVM)
CEL-SCI Corporation (CEL-SCI), incorporated on March 22, 1983, is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
Multikine
CEL-SCI's Multikine, is being developed for the treatment of cancer. It is a cancer immunotherapy drugs called Combination Immunotherapy because it combines active and passive immunity in one product. It is the only cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer. Multikine target the tumor micro-metastases for treatment failure. Multikine is also applicable in many other solid tumors.
New Manufacturing Facility
CEL-SCI's facility manufactures Multikine for CEL-SCI's Phase III clinical trial. CEL-SCI offers the use of the facility as a service to pharmaceutical companies and others, particularly those that need to fill and finish their drugs in a cold environment. Fill and finish is the process of filling injectable drugs in a sterile manner.
LEAPS
CEL-SCI's patented T-cell Modulation Process uses heteroconjugates to direct the body to choose a specific immune response. The heteroconjugate technology, referred to as LEAPS, is intended to stimulate the human immune system to fight bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer. Administered like vaccines, LEAPS combines T-cell binding ligands with small, disease associated and peptide antigens.
Using the LEAPS technology, CEL-SCI has created a peptide treatment for H1N1 (swine flu) hospitalized patients. This LEAPS flu treatment is designed to focus on the conserved, non-changing epitopes of the di! fferent strains of Type A Influenza viruses, including swine, avian or bird, and Spanish Influenza. CEL-SCI's LEAPS flu treatment contains epitopes.
Advisors' Opinion:- [By James E. Brumley]
Little TNI Biotech Inc. (OTCMKTS:TNIB) just gave bigger immunology players like Amgen, Inc. (NASDAQ:AMGN) or CEL-SCI Corporation (NYSEMKT:CVM) a new reason to worry. Though CVM and AMGN aren't exactly sweating bullets yet, TNIB has taken not a big step forward in terms biotechnological progress, but rather, has widened its net with a lateral expansion.
- [By Bryan Murphy]
Look out AbbVie Inc. (NYSE:ABBV), and Gilead Sciences, Inc. (NASDAQ:GILD), you may want to look over your shoulder as well. There's a new immunology player coming to town, and its name is CEL-SCI Corporation (NYSEMKT:CVM). Yes, AbbVie may be the name behind blockbuster drug Humira - with nearly $10 billion in sales in 2012 - while Gilead Sciences is saving HIV patients' lives with immunological therapies Stribild and Complera. But, small cap company CEL-SCI may be closer to launching its own immunology drug sooner than most investors realize.
- [By James E. Brumley]
When biotech-savvy investors think of immunology stocks, they tend to gravitate towards a name like Dendreon Corporation (NASDAQ:DNDN), which for all intents and purposes introduced the world's first cancer vaccine, Provenge, as a treatment for prostate cancer. Traders with a better-than-average knowledge of the immunology field may turn their attention to a company like CEL-SCI Corporation (NYSEMKT:CVM). CEL-SCI doesn't have a product on the market yet, but its head and neck cancer drug - which also uses immunology - is in Phase 3 testing right now, and looks very promising. There are other, and smaller, stocks within the world of immunology, however, that deserve a closer look from the market, and one of the most exciting ones further down the size scale is TNI Biotech Inc. (OTCMKTS:TNIB).
- [By Bryan Murphy]
Names like Amgen, Inc. (NASDAQ:AMGN) and CEL-SCI Corporation (NYSEMKT:CVM) may have pioneered and even mainstreamed the idea of cancer immunology, but the nature of the branch of biotechnology means any company could send CEL-SCI or Amgen back-pedaling. See, it's not about size or deep pockets in the world of biotech anymore. It's about know-how and an idea, which can just as easily be discovered and developed by a small company as they can be a large company. That's why AMGN and CVM at least need to keep a close eye on budding immunology competitor TNI Biotech Inc. (OTCMKTS:TNIB).
No comments:
Post a Comment